{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T18:43:29Z","timestamp":1773168209540,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chirurg"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Endokrine Tumoren und hier im Speziellen neuroendokrine Neoplasien des Gastrointestinaltraktes (GEP-NETs), Ph\u00e4ochromozytome (PCs), Paragangliome (PGL) und Schilddr\u00fcsentumoren sind Paradebeispiele f\u00fcr die Bedeutung von Molekularpathologie und Molekularbiologie f\u00fcr Diagnostik, Klassifikation und letztendlich auch die (chirurgische) Therapie dieser Erkrankungen. Bei GEP-NETs erfolgt das Grading anhand des Ki-67-Index. Dieser bestimmt die Art der molekularen Bildgebung (DOTA [1,4,7,10-Tetraazacyclododecan\u20111,4,7,10-tetraessigs\u00e4ure]\/DOPA [3,4-Dihydroxyphenylalanin]\/FDG[Fluordesoxyglukose]-PET[Positronenemissionstomographie]\/CT [Computertomographie]), die m\u00f6gliche Therapie (chirurgisch und\/oder Radiopeptidtherapie), antiproliferative und symptomkontrollierende Therapie mit Somatostatinanaloga und letztendlich auch die Prognose. PC\/PGL k\u00f6nnen heredit\u00e4r auftreten (MEN2A [multiple endokrine Neoplasie Typ\u00a02A], VHL [Von-Hippel-Lindau-Tumorsuppressor], NF1 [Neurofibromatose Typ\u00a01], SDH[Succinat-Dehydrogenase]-Mutationen), was die chirurgische Therapie und die pr\u00e4operative Medikation ma\u00dfgeblich beeinflusst. Die molekulare Bildgebung hat einen hohen Stellenwert und kann bei grenzwertiger Biochemie wegweisend sein. Auch Nebennierenrindenkarzinome k\u00f6nnen genetisch determiniert sein. Bei Schilddr\u00fcsentumoren ist v.\u00a0a. die Pathologie der C\u2011Zelle (C-Zell-Hyperplasie, medull\u00e4res Schilddr\u00fcsenkarzinom) hervorzuheben. Bei heredit\u00e4rer Erkrankung (FMTC [famili\u00e4res medull\u00e4res Schilddr\u00fcsenkarzinom], MEN[multiple endokrine Neoplasie]2) ist h\u00e4ufig eine fr\u00fche prophylaktische Operation notwendig und verhindert das Auftreten von fortgeschrittenen Karzinomen. Aber auch die Bestimmung des Resektionsausma\u00dfes bei follikul\u00e4ren L\u00e4sionen bzw. die Unterscheidung zwischen \u201enon-invasive follicular thyroid neoplasm with papillary-like nuclear features\u201c (NIFTPs) und follikul\u00e4ren Varianten des papill\u00e4ren Schilddr\u00fcsenkarzinoms kann mithilfe spezifischer Marker erfolgen. Insgesamt hat die Molekularpathologie eine zunehmende Bedeutung bei diesen Entit\u00e4ten und ist auch Inhalt laufender Forschungsprojekte.<\/jats:p>","DOI":"10.1007\/s00104-021-01512-8","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T14:46:29Z","timestamp":1633617989000},"page":"996-1002","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Endokrine und neuroendokrine Tumoren","Endocrine and neuroendocrine tumors"],"prefix":"10.1007","volume":"92","author":[{"given":"Philipp","family":"Riss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Scheuba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Strobel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"key":"1512_CR1","volume-title":"Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","author":"A Berruti","year":"2012","unstructured":"Berruti\u00a0A, Baudin\u00a0E, Gelderblom\u00a0H et al (2012) Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up"},{"key":"1512_CR2","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1245\/s10434-018-6829-3","volume":"25","author":"L Brammen","year":"2018","unstructured":"Brammen\u00a0L, Niederle\u00a0MB, Riss\u00a0P et al (2018) Medullary thyroid carcinoma: Do ultrasonography and F\u2011DOPA-PET-CT influence the initial surgical strategy? Ann Surg Oncol 25:3919\u20133927. https:\/\/doi.org\/10.1245\/s10434-018-6829-3","journal-title":"Ann Surg Oncol"},{"key":"1512_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/nejmoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin\u00a0ME, Pavel\u00a0M, \u0106wik\u0142a\u00a0JB et\u00a0al (2014) Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N\u00a0Engl J Med 371:224\u2013233. https:\/\/doi.org\/10.1056\/nejmoa1316158","journal-title":"N Engl J Med"},{"key":"1512_CR4","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1210\/jc.2007-2496","volume":"93","author":"K Cheung","year":"2008","unstructured":"Cheung\u00a0K, Roman\u00a0SA, Wang\u00a0TS et al (2008) Calcitonin measurement in the evaluation of thyroid nodules in the United States: a\u00a0cost-effectiveness and decision analysis. J\u00a0Clin Endocrinol Metab 93:2173\u20132180. https:\/\/doi.org\/10.1210\/jc.2007-2496","journal-title":"J Clin Endocrinol Metab"},{"key":"1512_CR5","unstructured":"ClinicalTrials.gov (2021) Study to evaluate the efficacy and safety of lutathera in patients with grade 2 and grade 3 advanced GEP-NET. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03972488. Zugegriffen: 22. Aug. 2021"},{"key":"1512_CR6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1055\/a-0604-2924","volume":"56","author":"Deutsche Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)","year":"2018","unstructured":"Deutsche Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Netzwerk Neuroendokrine Tumoren (NeT) e.V. (Patientenvertretung), Bundesorganisation Selbsthilfe NeuroEndokrine Tumoren e.V. (NET-sgh) (Patientenvertretung) et al (2018) Practice guideline neuroendocrine tumors - AWMF-Reg. 021-27. Z\u00a0Gastroenterol 56:583\u2013681. https:\/\/doi.org\/10.1055\/a-0604-2924","journal-title":"Z Gastroenterol"},{"key":"1512_CR7","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","volume":"30","author":"S Filetti","year":"2019","unstructured":"Filetti\u00a0S, Durante\u00a0C, Hartl\u00a0D et al (2019) Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:1856\u20131883. https:\/\/doi.org\/10.1093\/annonc\/mdz400","journal-title":"Ann Oncol"},{"key":"1512_CR8","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000443172","volume":"103","author":"R Garcia-Carbonero","year":"2016","unstructured":"Garcia-Carbonero\u00a0R, Sorbye\u00a0H, Baudin\u00a0E et al (2016) ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology 103:186\u2013194. https:\/\/doi.org\/10.1159\/000443172","journal-title":"Neuroendocrinology"},{"key":"1512_CR9","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/bjs.10414","volume":"104","author":"S Gaujoux","year":"2017","unstructured":"Gaujoux\u00a0S, Mihai\u00a0R, Carnaille\u00a0B et\u00a0al (2017) European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma. Br J Surg 104:358\u2013376. https:\/\/doi.org\/10.1002\/bjs.10414","journal-title":"Br J Surg"},{"key":"1512_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen\u00a0BR, Alexander\u00a0EK, Bible\u00a0KC et\u00a0al (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26:1\u2013133. https:\/\/doi.org\/10.1089\/thy.2015.0020","journal-title":"Thyroid"},{"key":"1512_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000475526","volume":"105","author":"RJ Hicks","year":"2017","unstructured":"Hicks\u00a0RJ, Kwekkeboom\u00a0DJ, Krenning\u00a0E et\u00a0al (2017) ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. Neuroendocrinology 105:295\u2013309. https:\/\/doi.org\/10.1159\/000475526","journal-title":"Neuroendocrinology"},{"issue":"1","key":"1512_CR12","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1097\/SLA.0000000000003237","volume":"274","author":"D Kaemmerer","year":"2021","unstructured":"Kaemmerer\u00a0D, Twrznik\u00a0M, Kulkarni\u00a0HR et\u00a0al (2021) Prior resection of the primary tumor prolongs survival after peptide receptor radionuclide therapy of advanced neuroendocrine neoplasms. Ann Surg 274(1):e45\u2013e53. https:\/\/doi.org\/10.1097\/SLA.0000000000003237","journal-title":"Ann Surg"},{"key":"1512_CR13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3389\/fendo.2019.00339","volume":"10","author":"CDC Kamilaris","year":"2019","unstructured":"Kamilaris\u00a0CDC, Stratakis\u00a0CA (2019) Multiple endocrine neoplasia type 1 (MEN1): an update and the significance of early genetic and clinical diagnosis. Front Endocrinol 10:339. https:\/\/doi.org\/10.3389\/fendo.2019.00339","journal-title":"Front Endocrinol"},{"key":"1512_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.18632\/genesandcancer.213","volume":"12","author":"A Kuchareczko","year":"2021","unstructured":"Kuchareczko\u00a0A, Kopczy\u0144ski\u00a0J, Kowalik\u00a0A et\u00a0al (2021) Are molecular tests necessary to diagnose NIFTP? Genes Cancer 12:39\u201350. https:\/\/doi.org\/10.18632\/genesandcancer.213","journal-title":"Genes Cancer"},{"key":"1512_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12022-017-9484-5","volume":"28","author":"AK Lam","year":"2017","unstructured":"Lam\u00a0AK (2017) Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours. Endocr Pathol 28:213\u2013227. https:\/\/doi.org\/10.1007\/s12022-017-9484-5","journal-title":"Endocr Pathol"},{"key":"1512_CR16","volume-title":"Surgical therapy of adrenal tumors: guidelines from the German Association of Endocrine Surgeons (CAEK)","author":"K Lorenz","year":"2019","unstructured":"Lorenz\u00a0K, Langer\u00a0P, Niederle\u00a0B et\u00a0al (2019) Surgical therapy of adrenal tumors: guidelines from the German Association of Endocrine Surgeons (CAEK)"},{"key":"1512_CR17","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s00104-018-0653-y","volume":"32","author":"TJ Musholt","year":"2018","unstructured":"Musholt\u00a0TJ, Bockisch\u00a0A, Clerici\u00a0T et\u00a0al (2018) Update of the S2k guidelines: surgical treatment of benign thyroid diseases. Chirurg 32:1313\u20131311. https:\/\/doi.org\/10.1007\/s00104-018-0653-y","journal-title":"Chirurg"},{"issue":"2","key":"1512_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00423-013-1139-5","volume":"399","author":"B Niederle","year":"2014","unstructured":"Niederle\u00a0B, Sebag\u00a0F, Brauckhoff\u00a0M (2014) Timing and extent of thyroid surgery for gene carriers of hereditary C cell disease\u2014a consensus statement of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg 399(2):185\u2013197. https:\/\/doi.org\/10.1007\/s00423-013-1139-5","journal-title":"Langenbecks Arch Surg"},{"key":"1512_CR19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/bjs\/znaa047","volume":"108","author":"MB Niederle","year":"2020","unstructured":"Niederle\u00a0MB, Riss\u00a0P, Selberherr\u00a0A et\u00a0al (2020) Omission of lateral lymph node dissection in medullary thyroid cancer without a\u00a0desmoplastic stromal reaction. Br J Surg 108:174\u2013181. https:\/\/doi.org\/10.1093\/bjs\/znaa047","journal-title":"Br J Surg"},{"key":"1512_CR20","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1089\/thy.2019.0785","volume":"30","author":"MB Niederle","year":"2020","unstructured":"Niederle\u00a0MB, Scheuba\u00a0C, Riss\u00a0P et\u00a0al (2020) Early diagnosis of medullary thyroid cancer: are calcitonin stimulation tests still indicated in the era of highly sensitive calcitonin immunoassays? Thyroid 30:974\u2013984. https:\/\/doi.org\/10.1089\/thy.2019.0785","journal-title":"Thyroid"},{"key":"1512_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000472254","volume":"105","author":"K \u00d6berg","year":"2017","unstructured":"\u00d6berg\u00a0K, Couvelard\u00a0A, Fave\u00a0GD et\u00a0al (2017) ENETS consensus guidelines for standard of care in neuroendocrine tumours: biochemical markers. Neuroendocrinology 105:201\u2013211. https:\/\/doi.org\/10.1159\/000472254","journal-title":"Neuroendocrinology"},{"key":"1512_CR22","doi-asserted-by":"publisher","DOI":"10.1159\/000464292","author":"S Partelli","year":"2017","unstructured":"Partelli\u00a0S, Bartsch\u00a0DK, Capdevila\u00a0J et\u00a0al (2017) ENETS consensus guidelines for standard of care in neuroendocrine tumours: surgery for small intestinal and pancreatic neuroendocrine tumours. Neuroendocrinology. https:\/\/doi.org\/10.1159\/000464292","journal-title":"Neuroendocrinology"},{"key":"1512_CR23","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel\u00a0M, \u00d6berg\u00a0K, Falconi\u00a0M et al (2020) Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:844\u2013860. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.304 (Approved by the ESMO Guidelines Committee: August 2007, last update March 2020. This publication supersedes the previously published version\u2014Ann Oncol. 2012;23(suppl 7):vii124\u2013vii130)","journal-title":"Ann Oncol"},{"key":"1512_CR24","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/jco.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke\u00a0A, M\u00fcller\u00a0H\u2011H, Schade-Brittinger\u00a0C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J\u00a0Clin Oncol 27:4656\u20134663. https:\/\/doi.org\/10.1200\/jco.2009.22.8510","journal-title":"J Clin Oncol"},{"key":"1512_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40336-013-0005-3","volume":"1","author":"V Rufini","year":"2013","unstructured":"Rufini\u00a0V, Treglia\u00a0G, Montravers\u00a0F, Giordano\u00a0A (2013) Diagnostic accuracy of [18F]DOPA PET and PET\/CT in patients with neuroendocrine tumors: a\u00a0meta-analysis. Clin Transl Imaging 1:111\u2013122. https:\/\/doi.org\/10.1007\/s40336-013-0005-3","journal-title":"Clin Transl Imaging"},{"key":"1512_CR26","volume-title":"WHO classification of tumours of endocrine orga\u00a0s","author":"RV Lloyd","year":"2017","unstructured":"Lloyd\u00a0RV, Osamura\u00a0RY, Kl\u00f6ppel\u00a0G, Rosai\u00a0J (2017) WHO classification of tumours of endocrine orga\u00a0s. IARC, Lyon"},{"key":"1512_CR27","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1002\/bjs.11348","volume":"107","author":"S Schimmack","year":"2020","unstructured":"Schimmack\u00a0S, Kaiser\u00a0J, Probst\u00a0P et al (2020) Meta-analysis of \u03b1\u2011blockade versus no blockade before adrenalectomy for phaeochromocytoma. Br J Surg 107:e102\u2013e108. https:\/\/doi.org\/10.1002\/bjs.11348","journal-title":"Br J Surg"},{"key":"1512_CR28","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00104-020-01230-7","volume":"91","author":"S Schimmack","year":"2020","unstructured":"Schimmack\u00a0S, Knoell\u00a0P, Kihm\u00a0L, Strobel\u00a0O (2020) Chirurgie der Nebennierenerkrankungen. Chirurg 91:783\u2013792. https:\/\/doi.org\/10.1007\/s00104-020-01230-7","journal-title":"Chirurg"},{"key":"1512_CR29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00104-020-01277-6","volume":"404","author":"JI Staubitz","year":"2020","unstructured":"Staubitz\u00a0JI, Clerici\u00a0T, Riss\u00a0P et al (2020) EUROCRINE\u00ae: adrenal surgery 2015\u20132019-\u00a0surprising initial results. Chirurg 404:385\u2013315. https:\/\/doi.org\/10.1007\/s00104-020-01277-6","journal-title":"Chirurg"},{"key":"1512_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/nejmoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg\u00a0J, El-Haddad\u00a0G, Wolin\u00a0E et al (2017) Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N\u00a0Engl J Med 376:125\u2013135. https:\/\/doi.org\/10.1056\/nejmoa1607427","journal-title":"N Engl J Med"},{"key":"1512_CR31","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1200\/jco.2021.39.15_suppl.4112","volume":"39","author":"JR Strosberg","year":"2021","unstructured":"Strosberg\u00a0JR, Caplin\u00a0ME, Kunz\u00a0PL et al (2021) Final overall survival in the phase 3 NETTER-1\u00a0study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors. J\u00a0Clin Oncol 39:4112. https:\/\/doi.org\/10.1200\/jco.2021.39.15_suppl.4112","journal-title":"J Clin Oncol"},{"key":"1512_CR32","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.73.6785","author":"V Subbiah","year":"2017","unstructured":"Subbiah\u00a0V, Kreitman\u00a0RJ, Wainberg\u00a0ZA et\u00a0al (2017) Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600\u2013mutant anaplastic thyroid cancer. J\u00a0Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2017.73.6785","journal-title":"J Clin Oncol"},{"key":"1512_CR33","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000471879","volume":"105","author":"A Sundin","year":"2017","unstructured":"Sundin\u00a0A, Arnold\u00a0R, Baudin\u00a0E et\u00a0al (2017) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine & hybrid imaging. Neuroendocrinology 105:212\u2013244. https:\/\/doi.org\/10.1159\/000471879","journal-title":"Neuroendocrinology"},{"key":"1512_CR34","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","volume":"26","author":"LDR Thompson","year":"2002","unstructured":"Thompson\u00a0LDR (2002) Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms. Am J Surg Pathol 26:551\u2013566. https:\/\/doi.org\/10.1097\/00000478-200205000-00002","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"1512_CR35","doi-asserted-by":"publisher","first-page":"E54","DOI":"10.1210\/jc.2009-2827","volume":"95","author":"M Troch","year":"2010","unstructured":"Troch\u00a0M, Koperek\u00a0O, Scheuba\u00a0C et\u00a0al (2010) High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. J\u00a0Clin Endocrinol Metab 95(9):E54\u2013E57. https:\/\/doi.org\/10.1210\/jc.2009-2827","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Der Chirurg"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-021-01512-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00104-021-01512-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-021-01512-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T16:44:55Z","timestamp":1634921095000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00104-021-01512-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,7]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1512"],"URL":"https:\/\/doi.org\/10.1007\/s00104-021-01512-8","relation":{},"ISSN":["0009-4722","1433-0385"],"issn-type":[{"value":"0009-4722","type":"print"},{"value":"1433-0385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,7]]},"assertion":[{"value":"9 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"P.\u00a0Riss, K.\u00a0Scheuba und O.\u00a0Strobel geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}